0000000000530557

AUTHOR

Erminia Baldacci

showing 7 related works from this author

Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report

2021

Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia (platelet count <100 × 109/l) in the absence of other causes or disorders associated. The incidence of ITP in pregnancy is one to two cases per 1000 gestations. ITP could be diagnosed before or during pregnancy; sometimes a relapse of a previously diagnosed ITP can occur. Intravenous immune globulins (IVIg) and corticosteroids are the standard frontline therapy because of their well known safety profile either for the mother or for the neonate. Treatments for refractory patients are limited by potential fetal risk. We report the case of a patient with ITP along pregnancy, refractory…

Pediatricsmedicine.medical_specialtyAdolescenteltrombopag pregnancy.EltrombopagBenzoateschemistry.chemical_compoundRefractoryPregnancyhemic and lymphatic diseasesMedicineHumansThrombopoietin receptorFetusPregnancyPurpura Thrombocytopenic Idiopathicbusiness.industryPlatelet CountIncidence (epidemiology)Pregnancy Complications HematologicInfant NewbornHematologyGeneral Medicinemedicine.diseaseHydrazineschemistryGestationPyrazolesFemalebusinessComplicationReceptors ThrombopoietinPrimary immune thrombocytopenia
researchProduct

Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations

2021

Introduction: In patients with primary immune thrombocytopenia (ITP), a short course of steroids is routinely given as first-line therapy. However, the response is often transient and additional therapy is usually needed. Thrombopoietin receptor agonists (TPO-RAs) are frequently used as second-line therapy, although there is little clinical guidance on the timing of their administration and on tapering/discontinuation of the drug. To provide clinical recommendations, we used the Delphi technique to obtain consensus for statements regarding administration and on tapering/discontinuation of second-line TPO-RAs among a group of Italian clinicians with expertise in management of ITP. Methods: T…

Thrombopoietin Receptor Agoniststherapybusiness.industryconsensus Delphi immune thrombocytopenia management second line therapy thrombopoietin receptor agonistsfood and beveragesconsensus; Delphi; immune thrombocytopenia; management; second line; therapy; thrombopoietin receptor agonistsHematologySettore MED/15DelphiImmune thrombocytopeniaSecond lineimmune thrombocytopeniaconsensusImmunologyconsensuMedicinethrombopoietin receptor agonistsDiseases of the blood and blood-forming organsIn patientsecond lineRC633-647.5businessmanagementOriginal Research
researchProduct

ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers

2021

AbstractConsidering the profound influence exerted by the ABO blood group system on hemostasis, mainly through the von Willebrand factor and factor VIII (FVIII) complex, we have conducted a study evaluating the possible role of blood type on the risk of inhibitor development in hemophilia A. A total of 287 consecutive Caucasian patients with severe hemophilia A (202 without FVIII inhibitors and 85 with FVIII inhibitors) followed at seven Italian Hemophilia Treatment Centers belonging to the Italian Association of Hemophilia Centers (AICE) were included in the study. A higher prevalence of O blood group was detected in patients without inhibitors as compared in inhibitor patients (55 vs. 30.…

Malecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyHemophilia ASevere hemophilia AABO Blood-Group SystemVon Willebrand factorhemic and lymphatic diseasesInternal medicineABO blood group systemABO blood group; hemophilia; inhibitors; risk factorshemophiliainhibitorsHumansMedicinerisk factorsIn patientBlood typebiologybusiness.industryABO blood groupHematologyinhibitorItalyHemostasisbiology.proteinFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Pain assessment and management in Italian Haemophilia Centres

2021

BACKGROUND: Although the widespread use of factor VIII/IX replacement therapy has significantly reduced the severity of arthropathy in persons with haemophilia (PWH), some develop degenerative joint changes, associated with significant pain. The aim of this survey was to investigate the management and perception of pain among Italian physicians who treat PWH. MATERIALS AND METHODS: Between September and October 2017, a questionnaire was distributed to 35 Italian haemophilia treatment centres (60 physicians). RESULTS: Fifty-three haemophilia specialists completed the survey. We found that there was good agreement (98.1%) on the need to investigate pain at each clinical visit, but there was h…

Factor IXItalyHumansPain Managementpain heamophiliaHemophilia Ablood coagulation disorders haemophilia pain perception pain management surveysHaemostasis and ThrombosisPain Measurement
researchProduct

Fostering drug.storage,preparation and treatment modalities improves adherence to treatment with turoctocog-alfa in patients with haemophilia A:resul…

2019

Haemophilia Adrug storagetreatment adherence
researchProduct

Diagnosis and treatment of chronic synovitis in patients with haemophilia: consensus statements from the Italian Association of Haemophilia Centres

2022

Although synovitis is recognized as a marker of joint disease activity, its periodic assessment is not included in routine clinical surveillance of patients with haemophilia (PwH). In order to evaluate the current knowledge and to identify controversial issues, a preliminary literature search by the Musculoskeletal Committee of the Italian Association of Haemophilia Centres (AICE) has been conducted. Statements have been established and sent to the Italian AICE members to collect their level of agreement or disagreement by a Delphi process. Thirty-seven consensus recommendations have been drafted. We found a general agreement on the indication to consider the presence of synovitis as a mark…

haemophilia; haemophilic arthropathy; synovitis; Chronic Disease; Consensus; Hemophilia A; Humans; Italy; Synovitishaemophilia haemophilic arthropathy synovitisConsensusSynovitisItalyChronic Diseasehaemophilic arthropathyhaemophiliaHumansHematologyHemophilia ABritish Journal of Haematology
researchProduct

Promoting physical activity in people with haemophilia: the MEMO (Movement for persons with haEMOphilia) expert consensus project.

2021

: Regular physical activity can increase joint stability and function, reduce the risk of injury, and improve quality of life of people with haemophilia (PwH). However, a recent review of the literature shows that appropriate physical activity and sport are not always promoted enough in the overall management of PwH. A group of Italian experts in haemophilia care undertook a consensus procedure to provide practical guidance on when and how to recommend physical exercise programmes to PwH in clinical practice. Three main topics were identified -haemophilia and its impact on movement, physical activity recommendations for PwH, and choice and management of sports activity in PwH- and ten state…

ConsensusrecommendationsQuality of Lifehaemophiliaphysical activityHumansProspective StudiessportHemophilia AExerciseHaemostasis and ThrombosisBlood transfusion = Trasfusione del sangue
researchProduct